[CME:Heparin-Induced Thrombocytopenia].

Area of Science:

• Immunology
• Hematology
• Pharmacology

Background:

• Heparin-induced thrombocytopenia (HIT) is a severe, potentially fatal immune-mediated adverse effect of heparin therapy.
• HIT is characterized by a significant decrease in platelet count (mean 60 x 10^9/L) typically occurring 5-10 days post-heparin exposure.
• HIT can lead to dangerous thrombotic events, including venous and arterial thrombosis, due to platelet activation by specific antibodies.

Purpose of the Study:

• To outline the diagnostic criteria and therapeutic strategies for Heparin-Induced Thrombocytopenia (HIT).
• To emphasize the importance of early recognition and management of HIT to prevent severe complications.

Main Methods:

• Diagnosis of HIT involves calculating the probability of HIT using the 4T Score.
• Laboratory confirmation includes the detection of HIT antibodies.
• Assessment of clinical presentation and laboratory findings.

Main Results:

• The 4T Score aids in estimating the likelihood of HIT.
• Laboratory tests confirm the presence of HIT antibodies.
• HIT is associated with significant morbidity and mortality if not managed promptly.

Conclusions:

• Immediate discontinuation of heparin is crucial in suspected HIT cases.
• Initiation of alternative anticoagulation therapy is essential for managing HIT.
• Prompt diagnosis and management of HIT can mitigate life-threatening complications.